Summary. This paper presents a survey of the biological potencies of a variety of naturally-occurring and semi-synthetic insulin analogues and a study of the joint biological action of some of these materials with native insulin. Biological activity was tested on isolated rat fat cells using lipogenesis from glucose as the metabolic index. A brief comparison using inhibition of fat cell lipolysis was included. The results indicated: 1. Analogue potencies varied considerably (0.4-100% insulin activity). Values obtained were mainly confirmatory but included two further B1-modified materials and a tricarbamylated insulin. The results supported previous indications on the relative roles of the A1, B1, and B29 residues of insulin for hormone activity. 2. Analogue bioactivities, whether assessed by stimulation of lipogenesis or inhibition of lipolysis, were similar for the four materials tested in both systems. The response of fat cells with respect to both metabolic indices occurred over a comparable range of insulin concentrations, with half maximal effects at 30-35 pmol 1-1 insulin. 3. The presence of modified insulins appeared to alter the biological action of native insulin in vitro. Small effects of both potentiation and antagonism were identified.
1 Present Address: The Medical Unit, The Princess Margaret Hospital, Christchurch, New Zealand from extensive studies using a group of insulins modified at the A1, B1, and B29 positions of the molecule in terms of their bioactivity [1] [2] [3] [4] [5] , receptor binding affinity [5, 6] , conformation [4, 7, 8] and metabolic clearance [9] .
The initial step in this in vitro study on the action of insulin analogues was to establish the biological potencies of 31 available materials from their ability to stimulate lipogenesis in isolated rat fat cells, most of these data being an independent confirmation of results published previously. The abilities of four of the analogues to inhibit adrenaline-stimulated lipolysis in fat cells were also investigated and compared with their lipogenic potencies.
Insulin appears to inhibit lipolysis in adipose tissue by a mechanism independent of glucose uptake [10, 11] and it is not clear whether the insulin receptor as well as the effector mechanism for the two processes is different. The anti-lipolytic action of insulin has been reported to occur at lower hormone concentrations [12, 13] than effects on glucose uptake. The experiments described here enabled us to compare the concentrations of insulin causing halfmaximal effects on these two metabolic effects in the same preparation of fat cells.
Finally, the established biological potencies of four AI, B29 modified insulins and proinsulin were used to design experiments investigating the effect of these analogues on the metabolic response of fat cells to native insulin. The availability of materials with the ability to modify insulin action at the tissue level could lead to a new approach to the treatment of diabetes mellitus. An analogy would be the successful use of analogues of acetylcholine to treat myasthenia gravis [14] . This treatment is based on the ability of compounds structurally related to acetylcholine to potentiate or increase the action of the neurotransmitter at the motor end-plate. [3-3H] glucose was obtained from the Radiochemical Centre, Amersham. Crude collagenase (138-211 units mg-1), was purchased from the Worthington Biochemical Corporation, New Jersey, and human serum albumin was a generous gift from the Blood Products Laboratory, Lister Institute, Hertfordshire. Adrenaline ("Injection", 5.46 mmol 1-1) was obtained from the St. Thomas' Hospital Pharmacy.
Materials and Methods

Materials
Repurified bovine insulin [15] used as reference standard, and the following semi-synthetic insulins [14, 15] were donated by D. Brandenburg, Wollforschungsinstitut, Aachen:
A1 acetyl insulin B29 acetyl insulin A1, B29 diaeetyl insulin A1-B29 desphe, m suberoyl insulin A1-B29 diamino suberoyl insulin A1-B29 dodecoyl insulin A1-B29 cystinyl insulin A1-B29 (butyl oxycarbonyl)2 cystinyl insulin A1-B29 (Z.lysyl alanyl lysyl) insulin Ax-B 1 diamino suberoyl insulin A1-B 1 (Z. lysyl alanyl lysyl) insulin The following materials were gifts from: D. G. Lindsay, University of Sussex, Brighton [2, 3, 16] .
A 1 carbamyl insulin A1 acetoacetyl insulin A1 succinyl insulin A 1 thiazolidyl insulin B1 carbamyl insulin B 1 acetoacetyl insulin B29 succinyl insulin A1, B1, B29 tricarbamyl insulin A1-B29 succinyl insulin A1-B29 adipoyl insulin R. Geiger, Farbwerke Hoechst A.G., Frankfurt [17, 18] :
[D-ala.] A1 insulin B~-3,5-diiodotyr. insulin J. C. Sodoyez, University of Liege, Belgium [19] :
[127I] monoiodoinsulin S. Emdin, Umea School of Medicine, Sweden [20] : hagfish insulin The Novo Industri A/S, Copenhagen: porcine proinsulin guinea pig insulin Materials were disolved in hydrochloric acid (1 mmol 1-1) and diluted in normal saline (150 mmol 1-1) containing human serum albumin (10 g 1-1) to concentrations of lg 1-1 or 4g 1-1 and stored frozen.
Isolated Fat Cell Assays
Isolated fat cells were prepared as described by Gliemann [21] from the epididymal fat pads of male Wistar rats weighing between 100 and 120 g and which had been fed ad lib#urn. The medium for cell isolation and incubation was Krebs-Ringer bicarbonate [22] in a gas phase of 95:5 (oxygen:carbon dioxide) or Krebs-Ringer HEPES [N-2-hydroxyethyl piperazine -N1-2 ethonesulphonic acid, 25 mmol 1-1] buffer, both containing albumin (10g 1-1). Cell numbers were determined using a haemocytometer and incubations performed in 20 ml polyethylene vials.
Lipogenesis from glucose was determined by the method of Moody et al. [23] Fat cell lipolysis was determined by measuring glycerol release following simulation by adrenaline (0.68~tmol 1-1). Incubations were performed in 2 ml Krebs-Ringer HEPES buffer containing albumin (30 gl-1), fat cells (<~ 1 • 105 cells ml-1), glucose (0 or 0.55 mmol 1-1) and hormone for 30 minutes at 37 ~ C. Aliquots of the medium were removed and added to perchloracetic acid (1.41 tool 1-1). The extract was neutralised using potassium hydroxide and glycerol concentration determined enzymatically [24] .
Biological potencies were determined by including bovine insulin (0-872 pmol 1-1) and appropriate dilutions of insulin analogues in an assay. Data in the linear portion of the log doseresponse curves were analysed using parallel-line bioassay techniques [25, 26] . The potency of an analogue relative to insulin was derived from the horizontal distance between fitted linear regression lines of response on log-dose for the materials. The results of analysis of variance and estimates of assay precision indicated assay validity.
The combined action of insulin and an analogue was investigated by comparing in one assay the abilities of insulin, an analogue and mixtures of the two materials to stimulate fat cell lipogenesis. Five concentrations of insulin and four concentrations of analogue were included as reference standards. Mixtures of insulin and analogue standard solutions were prepared in varying proportions and in initial experiments two dilutions of each mixture included in an assay. Subsequently one dilution of a mixture was assayed to enable investigation of a wider range of molar ratios of insulin: analogue. Fat cell responses were analysed using a likelihood ratio test [27] designed to detect any deviation from simple addition of the biological effects of two materials which have similar actions. The likelihood ratio test statistic was referred to the F-distribution for significance. The results were also plotted as isobols [28] i.e. plots of equi-effective doses of materials, to indicate visually whether any synergistic effect could be classified as antagonistic or potentiating. Results are the mean and range of estimates of potency obtained in 'n' assays Figure 1 illustrates the parallel log dose-response curves for the effects of insulin and two semi-synthetic derivatives on fat cell lipogenesis from glucose. The analogues studied appeared to retain the intrinsic activity of native insulin, i.e. achieved the same maximum response but varied in their potency relative to insulin as shown in Tables 1 and 2 . Analogues substituted at the B 1 position resembled native insulin in potency. Bl-carbamyl insulin showed slightly more bioactivity than insulin on isolated fat cells in keeping with full-activity reported in vivo [16] . The potency of B 1 acetoacetyl insulin was 85 per cent relative to insulin, comparable to reported values for B 1 succinyl andBt acetyl insulins [5] . Replacement of the B 1 residue with diiodotyrosine did not reduce bioactivity as we have reported elsewhere [29] . A1, B1, B29 tricarbamyl insulin exhibited a markedly reduced potency (10 per cent relative to insulin). This value is similar to that reported for trisuccinyl insulin but lower than for triacetyl insulin [5] . The potencies of the remaining analogues shown in Tables 1 and 2 were consistent with previously reported values [4, 5, 15, 17, 20, [30] [31] [32] [33] [34] . Table 3 lists the biological potencies of hagfish insulin and 3 A~, B29 modified insulins estimated from both their lipogenic and anti-lipolytic effects relative to insulin. Similar values were obtained using these two metabolic variables. The analogues appeared to be full agonists i. e. achieved the same maximum antilipolytic effect as insulin as shown in Figure 2 . The action of insulin in stimulating lipogenesis and inhibiting lipolysis in aliquots of the same preparation of fat cells is shown in Figure 3 . Half-maximal effects on both processes occurred at similar insulin concentrations (30-35 pmol 1-1) in two experiments under the conditions described. Figure 4 illustrates the independent and joint action of insulin and proinsulin on isolated fat cell lipogenesis. Responses produced by two dilutions of insulin/proinsulin mixtures were linear and parallel to the log dose-response curves of the reference preparations of the two hormones. This observation was true for all analogues studied. Analysis of responses by the likelihood ratio test gave the results shown in Table 4 and summarised in Table 5 . In seven control assays with insulin, no significant deviation from simple addition of biological effects was observed. In most assays (33-71 per cent) with analogues, however, their combined effect with insulin could not adequately be described by the additive model. A significant result was not observed on every occasion; for example A1, B29 diacetyl insulin appeared to modify insulin action significantly (p < 0.05) in four out of seven assays. A visual indication of the type of modifying action of this analogue is shown in Figure  5 . This "isobol" plot suggests a potentiating role for diacetyl insulin since the defined response was produced by lower concentrations of hormone when acting in combination with insulin than by either hormone acting alone. This can be contrasted to the pattern observed in control assays with insulin ( Figure  5b ) which indicates simple addition of biological effects. The isobol patterns (not shown) for the remaining analogues were consistent with a predominantly antagonistic action for A~-B29 suberoyl insulin but did not indicate a consistent effect for A 1-B29 dodecoyl insulin or proinsulin.
Discussion
Estimates of the biological activity of hormone analogues have enabled elucidation of areas of the molecule involved in maintaining structure and activity. The results presented here confirm previous observations of the importance of A 1 glycine and relative unimportance of the B 1 and B29 groups for the structure and activity of insulin. Substitution of A1 glycine with groups of increasing size caused a progressive decrease in activity. Potency estimates of modified insulins appear to be relatively independent of the tissue or metabolic effect of insulin used in their estimation. For exampie, the in vitro bioactivity of proinsulin has been reported as 2-4 per cent relative to insulin when assessed from various metabolic effects. These include stimulation of glucose uptake by rat diaphragm [33] ; glucose oxidation or lipogenesis in iso- lated fat cells [31, 33] ; amino acid uptake by cultured human fibroblasts [35] and inhibition of rat fat cell lipolysis at low concentrations or stimulation at high concentrations of hormone [36] . The in vivo hypoglycaemic activity of proinsulin, when corrected for the slower metabolism of this hormone, was similar in man [37] and the dog [9] to the bioactivity determined in vitro. It was observed in this study that the potencies of hagfish insulin and three of the A1, B29 modified insulins were similar whether estimated from stimulatory effects on lipogenesis from glucose or inhibition of adrenaline stimulated lipolysis in isolated rat fat cells. Rudman et al. [38] had reported a difference in potencies relative to insulin of desoctapeptide insulin and desala. B30, des asn. 121 insulin when determined from their effects on glucose oxidation and inhibition of lipolysis. In their study, however, different species (rat and hamster) were used as tissue source. Furthermore the analogues were reported to be partial agonists whereas later investigations [5, 6] have shown these materials to behave as full agonists of insulin. The in vitro biological activities of many analogues relative to insulin have been shown to agree with the relative binding affinities of the materials determined on isolated fat cells [5] and liver plasma membranes [6] . The altered biological activity of modified insulins therefore seems to reflect a change in their affinity for cell receptors, with the possible exception of hagfish insulin [20] . The observation that the relative bioactivities of some insulin derivatives are comparable whether estimated from effects on lipogenesis or lipolysis, despite the different "effector" mechanisms for these two processes would be consistent with the same receptor being involved in both actions.
Studies on the bioactivity of modified hormones allow not only investigation of structure-function relationships but also prediction of materials potentially useful for therapeutic or research purposes. For example, replacement of B 1 phe. with a radioactive residue should produce a fully active derivative and hence a valid tracer for studies on insulin action and metabolism, as shown for Bt-3,5-diiodotyr. Insulin [29] . Similarly, the observations [9] that the greater activity of A1, B29 modified insulins in vivo than in vitro could be explained by their reduced susceptibility to degradation might suggest a therapeutic use for the materials, either as longer-acting forms of the hormone or possibly as potentiators of insulin action through an ability to inhibit degradation of the native hormone. It therefore seemed desirable to investigate whether the biological activity of insulin could be potentiated or antagonised by analogues of the hormone. We have presented results suggesting that materials with this ability can be identified in an in vitro isolated cell system.
The combined effects of insulin and an analogue on fat cell lipogenesis were analysed by a likelihood ratio test and shown to deviate significantly from simple additivity. By comparison, simple addition of responses was observed in control experiments with insulin. The modifying action of the analogues was not always reproducible, being significant in 33-71 per cent of assays; this lack of reproducibility possibly being due to collagenase effects on the cell membrane. The type of action, i.e. potentiation or antagonism, was indicated by isobol patterns for A1, B29 diacetyl insulin (potentiation) and A1-B29 suberoyl insulin (predominantly an antagonist). No clear effects of proinsulin or AI-B29 dodecoyl insulin were observed by this method. These overall results suggest that the materials studied were not strong synergists. This may explain the discrepancy between these results and those of Gliemann and Gammeltoft [5] who suggested that AI-B29 dodecoyl insulin had purely additive effects with insulin, as did various A 1 modified insulins [8] and hagfish insulin [20] . Their approach (addition of sub-maximally stimulating concentrations of insulin and analogue) would not allow sufficiently rigorous statistical analysis to determine whether the net response was simply additive or consistent with significant potentiation or antagonism. As pointed out by these workers [5, 8] , a model in which two drugs act on the same receptor as full agonists, although possibly differing in affinity, would require that the materials have additive effects. This model, however, assumes that no interaction occurs between adjacent receptor sites. The observations presented here suggest that the basic assumption of independent receptor sites may not be applicable to insulin's action on fat cells.
